NCT04476953
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
At risk: Primary completion moved at least 5 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 11 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 10 words
- Primary and study completion pushed from Sep 2026 to Mar 2027
- Notable Primary and study completion dates: Sep 2025 to Sep 2026v11
- Notable Primary completion date: Dec 2024 to Sep 2025v10
- Minor Trial status: Enrolling by Invitation to Active, Not Recruitingv9
- Notable Primary completion date: Sep 2023 to Dec 2024
- Study completion date: Sep 2023 to Sep 2025
Show 5 earlier versionsHide 5 earlier versions
- Notable Primary and study completion dates pushed to Sep 2023v6
- Notable Primary completion date: Jan 2022 to Sep 2022
- Enrollment target: 70 to 80
- Study completion date: Jul 2022 to Jul 2023
- Minor Primary completion date: Jul 2021 to Jan 2022
- Study completion date: Jul 2021 to Jul 2022
- Notable Eligibility criteria expanded, about 40 words
- Secondary endpoint revised
- Study description shortened, about 6 words
- Study title revised
- Notable Eligibility criteria expanded, about 400 words
- Start date changed from estimate of Jul 2020 to Aug 3, 2020
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Serious Adverse Events
Timeframe: 6 months
Change in oxygenation status
Timeframe: baseline, Day 3, 7, 10, 14, 17 and 30; Months 3 and 6
Secondary (1)
CoV Severity Category
Arms and interventions
Treatment GroupExperimental
Subjects will receive treatment drug Fisetin
Placebo GroupPlacebo comparator
Subjects will receive placebo
Drugs: Placebo, Fisetin
Sites
1 site in 1 country
- Mayo Clinic in RochesterRochester, Minnesota, United States